1-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride
• 英文别名: N-(dimethyl-aminopropyl)-N'-ethylcarbodiimide hydrochloride；N-(N,N-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride；[(N,N-dimethylamino)propyl]ethylcarbodiimide hydrochloride；3-[N-dimethylaminopropyl]-N-ethylcarbodiimide hydrochloride；1-(N,N-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride；[1-ethyl-3-(dimethylaminopropyl)-carbodiimide] hydrochloride；01-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride；N-ethyl-N'-dimethylaminopropylcarbodiimide hydrochloride；ethyl(dimethylaminopropyl)carbodiimide hydrochloride；dimethylaminopropylethylcarbodiimide hydrochloride；1-ethyl-3-(dimethylaminopropyl)-carbodiimide · hydrochloride；1-ethyl-3-(N,N-dimethylaminopropyl)carbodiimide hydrochloride；hydrochloric acid 1-(dimethylaminopropyl)-3-ethylcarbodiimide；dimethylaminopropyl-3-ethylcarbodiimide hydrochloride
• 化学式: C₈H₁₇N₃*ClH
• 分子量: 191.704
• InChiKey: WEPXFRSKOOIELF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  28
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride 、 N-iodopropargyloxycarbonyl alanine 、 辛醇 在 4-二甲氨基吡啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以74%的产率得到N-iodopropargyloxycarbonyl alanine n-octyl ester
  参考文献：
  名称：

  Preparation and use of N-iodopropargyl oxycarbonyl amino acid esters and

  摘要：

  化合物的抗微生物化合物的公式为 ##STR1## 其中 R.sup.1 从 H，较低的 (C.sub.1 -C.sub.4)烷基，烷基芳基，CH.sub.2 OR，CH.sub.2 SR 和 CH(CH.sub.3)OR 组成的群中选择; 而 R，R.sup.2 和 R.sup.3 分别选择自 H，(C.sub.1 -C.sub.4)烷基，芳基，芳基烷基，烷芳基 和 卤代丙炔基。

  公开号：

  US05209930A1
• 作为试剂：
  描述：

  7,7-dimethyl-2,3-bis(thiophen-2-yl)-5,6-bis(trifluoromethyl)-2,5-norbornadiene 在 4-二甲氨基吡啶 、 sodium hydroxide 、 正丁基锂 、 1-dimethylaminopropyl-3-ethylcarbodiimide hydrochloride 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 75.0h， 生成 (4-Nitrophenyl) 5-[7,7-dimethyl-3-[5-(4-nitrophenoxy)carbonylthiophen-2-yl]-5,6-bis(trifluoromethyl)-2-bicyclo[2.2.1]hepta-2,5-dienyl]thiophene-2-carboxylate
  参考文献：
  名称：

  Synthesis of New Photoresponsive Polymers Containing Trifluoromethyl-Substituted Norbornadiene Moieties

  摘要：

  Polymers containing trifluoromethyl. (CF3)-substituted donor-acceptor NBD moieties in the side chain or in the main chain were synthesized by substitution or addition of a CF3-NBD-carboxylic acid derivative or by polycondensation of a CF3-NBD-dicarboxylic acid derivative. The photoisomerization of the NBD moieties in these polymers proceeded very smoothly to give the corresponding QC moieties. Furthermore, the NBD moieties exhibited efficient fatigue resistance.

  DOI：

  10.1021/ma0214207

文献信息

• [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2021158707A1

  公开（公告）日：2021-08-12

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及化合物和方法，用于调节dmpk的表达，并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子，具有第一末端、第二末端和寡聚骨架，其中：a）第一末端包括一种DNA结合基团，能够非共价结合到核苷酸重复序列CAG或CTG；b）第二末端包括结合到调节分子的蛋白结合基团，该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达；c）寡聚骨架包括连接第一末端和第二末端的连接物。
• Primary Amines as Renin Inhibitors
  申请人：Bezencon Olivier

  公开号：US20090088457A1

  公开（公告）日：2009-04-02

  The invention relates to novel primary amine derivatives and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  这项发明涉及新型一次胺衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一种或多种化合物的药物组合物，特别是它们作为肾素抑制剂的用途。
• Secondary Amines as Renin Inhibitors
  申请人：Bezencon Olivier

  公开号：US20090176823A1

  公开（公告）日：2009-07-09

  The invention relates to novel secondary amine derivatives of formula (I) and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  这项发明涉及公式（I）的新型二级胺衍生物及其作为药物组成物中的活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有其中一个或多个这些化合物的药物组成物，特别是它们作为肾素抑制剂的用途。
• [EN] FUSED RING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS ET UTILISATION DE CEUX-CI
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009125873A1

  公开（公告）日：2009-10-15

  The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.

  本发明旨在提供一种葡萄糖激酶激活剂，可用作药用剂，如用于预防或治疗糖尿病、肥胖等疾病的药剂。本发明提供一种包含由式(I)表示的化合物的葡萄糖激酶激活剂：其中每个符号在规范中有定义，或其盐或前药。
• Pna-Neamine Conjugates and Methods for Producing and Using the Same
  申请人：Decout Jean-Luc

  公开号：US20070225239A1

  公开（公告）日：2007-09-27

  The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.

  本发明涉及一种由肽核酸（PNA）部分和奈胺衍生物部分组成的共轭物的方法和组合物。还提供了使用这种共轭物来调节靶核酸分子活性以及预防或治疗与异常核酸分子相关的疾病的方法。